Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:AGLE

Aeglea BioTherapeutics (AGLE) Stock Price, News & Analysis

Aeglea BioTherapeutics logo

About Aeglea BioTherapeutics Stock (NASDAQ:AGLE)

Advanced Chart

Key Stats

Today's Range
N/A
50-Day Range
$9.47
$13.76
52-Week Range
N/A
Volume
43,300 shs
Average Volume
95,409 shs
Market Capitalization
$48.64 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Receive AGLE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Aeglea BioTherapeutics and its competitors with MarketBeat's FREE daily newsletter.

AGLE Stock News Headlines

Spyre Therapeutics Advances IBD Treatment Pipeline
Forget Nvidia, This “Ghost Town” Company Holds the Key to the AI Boom
Cold War Discovery Could Unlock $100 Trillion in Wealth Jeff recently traveled to an American ghost town to investigate this crazy Cold War story… Because it could hold the key to the entire $100 trillion AI boom. It involves an American ghost town with just 30 people… And a new twist to the AI boom that could make a lot of people rich.
Bridge Biotherapeutics Inc.
Spyre Therapeutics Announces $180 Million Private Placement
See More Headlines

AGLE Stock Analysis - Frequently Asked Questions

Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE) announced its quarterly earnings data on Thursday, November, 4th. The biotechnology company reported ($7.75) EPS for the quarter, missing analysts' consensus estimates of ($7.00) by $0.75. The biotechnology company had revenue of $1.40 million for the quarter, compared to analysts' expectations of $1.38 million. Aeglea BioTherapeutics had a negative trailing twelve-month return on equity of 132.05% and a negative net margin of 22,195.36%.

Shares of Aeglea BioTherapeutics reverse split on the morning of Friday, September 8th 2023.The 1-25 reverse split was announced on Thursday, September 7th 2023. The number of shares owned by shareholders was adjusted after the market closes on Thursday, September 7th 2023. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split.

Aeglea BioTherapeutics (AGLE) raised $60 million in an IPO on Thursday, April 7th 2016. The company issued 3,500,000 shares at $16.00-$18.00 per share. UBS Investment Bank, BMO Capital Markets and Wells Fargo Securities acted as the underwriters for the IPO and Needham & Company was co-manager.

Based on aggregate information from My MarketBeat watchlists, some other companies that Aeglea BioTherapeutics investors own include Bristol Myers Squibb (BMY), Athenex (ATNX), Dynavax Technologies (DVAX), Enterprise Products Partners (EPD), Amarin (AMRN), Axsome Therapeutics (AXSM) and AbbVie (ABBV).

Company Calendar

Last Earnings
11/04/2021
Today
7/12/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:AGLE
CIK
1636282
Employees
69
Year Founded
N/A

Profitability

EPS (Trailing Twelve Months)
($75.59)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$83.82 million
Net Margins
-22,195.36%
Pretax Margin
-27,931.12%
Return on Equity
-132.05%
Return on Assets
-146.87%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
4.59
Quick Ratio
4.59

Sales & Book Value

Annual Sales
$2.33 million
Price / Sales
0.00
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
($60.61) per share
Price / Book
N/A

Miscellaneous

Outstanding Shares
4,050,000
Free Float
3,782,000
Market Cap
$48.64 million
Optionable
Optionable
Beta
2.57

Social Links

A Beginner's Guide to Investing in Cannabis Cover

Unlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.

Get This Free Report

This page (NASDAQ:AGLE) was last updated on 7/12/2025 by MarketBeat.com Staff
From Our Partners